Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates, clinicians may ...

GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, ...

GlaxoSmithKline has received approval in Japan for its key respiratory product Seretide/Advair Diskus and its anti-thrombotic Arixtra, a move which the company says should make a significant ...

Results of the European INSPIRE (Investigating New Standards for Prophylaxis in Reduction of Exacerbations) study, published in the American Journal of Respiratory and Critical Care Medicine (2008: ...

GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...

Lagos — GLAXOSMITHKLINE Pharmaceutical Nigeria Plc (GSK), one of the leading pharmaceutical companies would today launch its anti-asthmatic drug seretide diskus, in the country. According to a ...

GlaxoSmithKline’s ageing respiratory blockbuster Advair has been living a charmed life since going off patent years ago - but as yet no-one has been able to get a generic rival approved in the key US ...

Seretide diskus, a combination inhaler and the world's biggest selling anti-asthmatic medication from the stable of GlaxoSmithkline Pharmaceutical Nigeria PLC (GSK), is set to be launched into the ...

Mylan has become the first company to launch a generic version of GlaxoSmithKline's (GSK) big-selling respiratory drug Seretide in the UK. Seretide (salmeterol xinafoate/fluticasone propionate) – sold ...

This study has demonstrated that doubling the dose of Seretide™ administered via the Diskus™ inhaler over a short period is safe and well tolerated. Whilst this is not a recommended treatment approach ...